Pfizer Inc. (NYSE:PFE) shares are trading flat during Wednesday’s premarket session as traders weigh mixed Phase 3 trial headlines alongside a firmer overnight tape. Here’s what investors need to know.
- Pfizer stock is showing downward bias. Where is PFE stock headed?
What Are the Latest Phase 3 Results for Pfizer?
On Monday, the company reported mixed topline Phase 3 results for its investigational antibody-drug conjugate sigvotatug vedotin in the SigVie-002 study in previously treated advanced non-squamous non-small cell lung cancer. The trial missed its primary overall survival endpoint versus docetaxel in the overall population, though second-line patients (about two-thirds of participants) showed a stronger trend toward improved overall survival and progression-free survival.
Pfizer also flagged that an exploratory analysis failed to show a clear relationship between integrin beta-6 (IB6) expression levels and treatment response, keeping the “who benefits” question open. Detailed trial findings are expected at a future medical meeting, which can become the next sentiment checkpoint for the program.
Critical Price Levels to Watch for PFE Stock
At $24.77, the stock is trading below every major moving average tracked here—about 3.8% under the 20-day SMA ($25.74), 5.3% under the 50-day SMA ($26.16), 7% under the 100-day SMA ($26.65), and 4.3% under the 200-day SMA ($25.88). That “below the stack” posture keeps rallies more likely to run into supply until price can reclaim at least the 20-day/200-day zone.
MACD is the cleaner momentum read right now: it’s below its signal line with a negative histogram, which typically means upside pressure is fading versus the prior upswing unless buyers can reassert control. Structurally, the longer-term backdrop is mixed—there’s still a golden cross from October 2025 (50-day SMA above the 200-day SMA), but the nearer-term crossover has turned bearish with the 20-day SMA below the 50-day SMA.
- Key Resistance: $27.50 — a round-number area above the main moving-average cluster where rebounds can stall
- Key Support: $24.00 — a nearby round-number level just above the 52-week low zone ($23.11) where buyers may try to defend
What Is Pfizer and How Does It Operate?
Pfizer is one of the world’s largest pharmaceutical firms, with annual sales of roughly $60 billion. Today, prescription drugs and vaccines make up most of its business, and its scale means pipeline updates can matter even when they don’t immediately change near-term revenue.
Top sellers include the pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis, and the company sells globally with international markets representing about 40% of total sales. In that context, mixed oncology readouts like SigVie-002 tend to be judged on whether they expand the long runway—Pfizer is also evaluating sigvotatug vedotin in a Phase 3 combination study with pembrolizumab in first-line advanced NSCLC.
Pfizer Benzinga Edge Rankings: Strengths and Weaknesses
Below is the Benzinga Edge scorecard for Pfizer, highlighting its strengths and weaknesses compared to the broader market:
- Momentum: Weak (Score: 23.92) — The stock’s trend profile is soft, lining up with price sitting below key moving averages.
- Quality: Neutral (Score: 37.24) — A middle-of-the-road quality read suggests the market isn’t assigning a clear “best-in-class” premium here.
- Value: Neutral (Score: 36.06) — The value score points to a more balanced setup rather than a deep-value or high-premium extreme.
- Growth: Weak (Score: 16.43) — The growth profile screens poorly versus the broader market, which can cap enthusiasm on rallies.
The Verdict: Pfizer’s Benzinga Edge signal reveals a weaker-tilted profile, led by soft Momentum and Growth scores. For longer-term bulls, the chart likely needs to reclaim key moving averages to improve the momentum backdrop, while bears will focus on whether $24.00 holds on any risk-off tape.
Pfizer Stock Price Movement in Premarket Trading
PFE Stock Price Activity: Pfizer shares were up 0.32% at $24.80 during premarket trading on Wednesday, according to Benzinga Pro data.
Image: Shutterstock
